Jiangsu Hengrui Medicine Co Ltd (600276.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE0000014W7

Price
46.06 CNY
Market cap
299.82 bn CNY
P/E (2025)
38.88
P/S (2025)
9.54
Dividend yield
0.43 %
Net margin
24.53 %
Return on equity (ROE)
12.58 %
Return on assets (ROA)
11.04 %

Jiangsu Hengrui Medicine Co Ltd financials

Fiscal year20242025
Revenue27.98 bn CNY31.43 bn CNY
Gross profit24.10 bn CNY26.67 bn CNY
Operating income7.49 bn CNY8.02 bn CNY
EBIT6.48 bn CNY8.02 bn CNY
Net income6.34 bn CNY7.71 bn CNY
Diluted EPS – continuing operations1.00 CNY1.18 CNY

Full history since 1997, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Jiangsu Hengrui Medicine Co Ltd

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.

Jiangsu Hengrui Medicine Co Ltd stock (600276.SS): P/E, revenue, dividend | finmetric